AlphaStocks
4.0
Weak

BIO-RAD LABORATORIES, INC. (BIO)

Health Care / Life Sciences Tools & Services

S&P MidCap 400

$282.01

Below average on several measures. Research carefully.

Weak

Score based on 5 of 5 models — high confidence

#859out of 1125 in Health Care

Is BIO-RAD LABORATORIES, INC. a Good Investment in 2026?

BIO-RAD LABORATORIES, INC. (BIO) scores 4.0 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Greenblatt Magic Formula model rates BIO-RAD LABORATORIES, INC. as Strong (Top 25% (rank 19%)). The Buffett model is the least favorable, rating it Neutral. BIO-RAD LABORATORIES, INC. ranks #859 out of 1125 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E10.1ROE9.7Market Cap8B

Valuation

Trades at 10x earnings — near sector median of 25x.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Attractive

35% below fair value

Lynch

Attractive

PEG 0.3 · Fast Grower

Greenblatt

Strong

Top 25% (rank 19%)

Frequently Asked Questions

Is BIO-RAD LABORATORIES, INC. (BIO) a good investment?
Based on AlphaStocks' composite analysis, BIO-RAD LABORATORIES, INC. (BIO) scores 4.0 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trades at 10x earnings — near sector median of 25x.
What is BIO-RAD LABORATORIES, INC.'s Piotroski F-Score?
BIO-RAD LABORATORIES, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is BIO overvalued or undervalued?
A precise fair value estimate is not available for BIO. Trades at 10x earnings — near sector median of 25x.
How does BIO compare to other Health Care stocks?
BIO-RAD LABORATORIES, INC. ranks #859 out of 1125 stocks in the Health Care sector, placing it in the top 76% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about BIO?
AlphaStocks evaluates BIO using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Attractive; Lynch: Attractive; Greenblatt Magic Formula: Strong. These models are combined into a single composite score of 4.0/10.

Similar Stocks

BFAMAZNKLIC

Compare BIO with

BIO vs BFAMBIO vs AZNBIO vs KLIC

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer